Novartis AG Gets FDA OK To Market Exelon Dow Jones Newswires EAST HANOVER, N.J. -- Novartis AG's (Z.NOV) Novartis Pharmaceuticals Corp. received Food and Drug Administration approval to market Exelon, a cholinesterase inhibitor for the treatment of patients with mild to moderate Alzheimer's disease.
In a press release Friday, the company said Exelon is now cleared for marketing in nearly 70 countries.
The market potential for Alzheimer's diagnostics (screening and monitoring therapy) is estimated to be $6-800M in the US alone. Quite frankly, I didn't acquire this stock with the drug therapy in mind...rather to play the diagnostic products. Unless NYMX gets a BIG Pharma partner to develop any compound, they should stick to the diagnostic side. The Serex thing gives them a number of new and exciting options there. Hey, just one investors opinion...p.s. love your screen name.